[go: up one dir, main page]

MX2018010194A - Microsferas de buprenorfina de liberacion sostenida (srbm) y metodos de uso de las mismas. - Google Patents

Microsferas de buprenorfina de liberacion sostenida (srbm) y metodos de uso de las mismas.

Info

Publication number
MX2018010194A
MX2018010194A MX2018010194A MX2018010194A MX2018010194A MX 2018010194 A MX2018010194 A MX 2018010194A MX 2018010194 A MX2018010194 A MX 2018010194A MX 2018010194 A MX2018010194 A MX 2018010194A MX 2018010194 A MX2018010194 A MX 2018010194A
Authority
MX
Mexico
Prior art keywords
srbm
sustained release
methods
release buprenorphine
microspheres
Prior art date
Application number
MX2018010194A
Other languages
English (en)
Inventor
Finn Andrew
Vasisht Niraj
Original Assignee
Biodelivery Sciences Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biodelivery Sciences Int Inc filed Critical Biodelivery Sciences Int Inc
Publication of MX2018010194A publication Critical patent/MX2018010194A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)

Abstract

La presente invención se dirige a una formulación de micro esferas de buprenorfina de liberación sostenida (SRBM)capaz de entregar buprenorfina, un metabolito, o un profármaco de la misma durante una duración de aproximadamente 7 días aproximadamente 6 meses.
MX2018010194A 2016-02-23 2017-02-23 Microsferas de buprenorfina de liberacion sostenida (srbm) y metodos de uso de las mismas. MX2018010194A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662298777P 2016-02-23 2016-02-23
PCT/US2017/019110 WO2017147285A1 (en) 2016-02-23 2017-02-23 Sustained release buprenorphine microspheres (srbm) and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2018010194A true MX2018010194A (es) 2019-06-12

Family

ID=58213387

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010194A MX2018010194A (es) 2016-02-23 2017-02-23 Microsferas de buprenorfina de liberacion sostenida (srbm) y metodos de uso de las mismas.

Country Status (8)

Country Link
US (4) US20170239240A1 (es)
EP (1) EP3419596A1 (es)
JP (2) JP2019510008A (es)
CN (1) CN109069416A (es)
AU (1) AU2017223606A1 (es)
CA (1) CA3015488A1 (es)
MX (1) MX2018010194A (es)
WO (1) WO2017147285A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11030218B2 (en) * 2017-08-10 2021-06-08 Hitachi, Ltd. Computer system and data processing method
WO2020183718A1 (ja) * 2019-03-14 2020-09-17 エム・テクニック株式会社 Ｐｌｇａ微粒子、その徐放性製剤及びその製造方法
EP3936112A1 (en) 2020-07-07 2022-01-12 Occlugel Hydrophilic degradable microspheres for delivering buprenorphine
CN115317453A (zh) * 2022-09-01 2022-11-11 广东嘉博制药有限公司 一种缓释微球制剂及其制备方法与用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5741590A (en) 1989-05-04 1990-11-29 Southern Research Institute Improved encapsulation process and products therefrom
EP1212061B1 (en) 1999-08-27 2004-10-27 Southern Research Institute Injectable buprenorphine microparticle compositions and their use in reducing consumption of heroin and alcohol
WO2005003180A2 (en) 2003-04-10 2005-01-13 Pr Pharmaceuticals A method for the production of emulsion-based micro particles
US20050048115A1 (en) * 2003-08-27 2005-03-03 Murty Mangena Buprenorphine microspheres
EP2331082B1 (en) 2008-09-11 2021-01-06 Evonik Corporation Solvent extraction microencapsulation with tunable extraction rates
CA2737484C (en) 2008-09-18 2017-10-10 Surmodics Pharmaceuticals, Inc. Microencapsulation process with solvent and salt
WO2010085607A1 (en) 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Continuous double emulsion process for making microparticles
US20130059008A1 (en) 2009-01-23 2013-03-07 Jeffrey L. Atkinson Drying methods for tuning microparticle properties
ES2764971T3 (es) 2009-12-22 2020-06-05 Evonik Corp Proceso basado en emulsión para la preparación de micropartículas y conjunto de cabezal de trabajo para su uso con el mismo
US20120082731A1 (en) 2010-09-30 2012-04-05 Adrian Raiche Method For Removing Residual Organic Solvent From Microparticles
CN104772056A (zh) 2010-12-23 2015-07-15 赢创有限公司 用来制备乳化液的设备和方法
US9566241B2 (en) * 2012-02-21 2017-02-14 Auburn University Buprenorphine nanoparticle composition and methods thereof
US9393211B2 (en) * 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same

Also Published As

Publication number Publication date
CA3015488A1 (en) 2017-08-31
AU2017223606A1 (en) 2018-09-13
WO2017147285A9 (en) 2017-09-28
US20200352935A1 (en) 2020-11-12
US20170239240A1 (en) 2017-08-24
WO2017147285A1 (en) 2017-08-31
US20190262333A1 (en) 2019-08-29
JP2019510008A (ja) 2019-04-11
US20220071988A1 (en) 2022-03-10
EP3419596A1 (en) 2019-01-02
CN109069416A (zh) 2018-12-21
JP2022071088A (ja) 2022-05-13

Similar Documents

Publication Publication Date Title
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
GT201600137A (es) Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina
MX2016014320A (es) Composiciones de suspension de liberacion prolongada.
EP3359241A4 (en) FORMULATIONS OF PTHRP ANALOGUE, TRANSDERMAL PLASTERS AND USES THEREOF
CL2016001895A1 (es) Compuestos
CR20160477A (es) Nanopartículas terapéuticas que comprenden un agente terapéutico, y métodos para su elaboración y uso
PH12017502376A1 (en) Oral solid formulation containing irinotecan and method of preparing the same
MX2017001553A (es) Derivados de heterociclico opcionalmente condensados de pirimidina utiles para el tratamiento de enfermedades inflamatorias, metabolicas oncologicas y autoinmunitarias.
MX2018010194A (es) Microsferas de buprenorfina de liberacion sostenida (srbm) y metodos de uso de las mismas.
SG10201902203VA (en) Eutectic formulations of cyclobenzaprine hydrochloride
PH12016501841A1 (en) Immunosuppressant formulation
UY36003A (es) Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina.
PH12017500451A1 (en) Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl) oxy)-n, 2-dimethylbenzofuran -3- carboxamide
NZ731060A (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
MX2016017142A (es) Dispersion solida de allisartan isoproxilo y composicion farmaceutica que comprende la misma.
NZ712341A (en) A crystalline form of an anxiolytic compound
MX2022010827A (es) Composiciones de microesferas de gas encapsulado en lipidos y metodos relacionados.
PH12017501767A1 (en) Combination dosage form of a mu opioid receptor antagonist and an opioid agent
UA117233C2 (uk) Композиція з тривалим вивільненням лоразепаму
CO2017001236A2 (es) Composición que comprende partículas a base de nitrato de amonio y un agente gelificante
JO3621B1 (ar) مركبات وتركيبات على هيئة عوامل مساعدة لمستقبل 7 يشبه toll
MY163393A (en) Pharmaceutical formulations of telmisartan and process for preparing the same
IN2013CH05440A (es)